drugset / Trial / NCT07198867
A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Recruiting
20 enrolled
First Affiliated Hospital of Zhejiang University
Shanghai AbelZeta Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label study to evaluate the safety and efficacy of A-CAR028 in relapsed/refractory acute myeloid leukemia patients
Timeline
- Start
- 2025-09-30
- Primary completion
- 2026-12-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | A-CAR028 | Cell therapy | — | Intravenous |